iBio, Inc. (NYSEAMERICAN:IBIO) Short Interest Update

iBio, Inc. (NYSEAMERICAN:IBIO) saw a significant increase in short interest in May. As of May 31st, there was short interest totalling 95,500 shares, an increase of 18.5% from the May 15th total of 80,600 shares. Based on an average daily trading volume, of 3,760,000 shares, the short-interest ratio is currently 0.0 days. Approximately 1.1% of the company’s shares are sold short.

Analyst Ratings Changes

Separately, StockNews.com started coverage on iBio in a research report on Wednesday, March 27th. They issued a “sell” rating for the company.

iBio Stock Performance

Shares of iBio stock opened at $2.30 on Tuesday. iBio has a 12 month low of $1.02 and a 12 month high of $15.99. The company has a debt-to-equity ratio of 0.04, a quick ratio of 0.91 and a current ratio of 0.91.

iBio (NYSEAMERICAN:IBIO) last issued its quarterly earnings results on Monday, May 13th. The company reported ($0.71) earnings per share (EPS) for the quarter.

About iBio

iBio, Inc, a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel.